Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up evaluation
article
OA: closed
CC0
⤵ 10 in-corpus citations
AI-generated summary
This study evaluated the efficacy and safety of goserelin acetate combined with endometrial ablation for dysfunctional uterine bleeding over a three-year period.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectiveTo report the results of a 3-year follow-up evaluation of a trial comparing goserelin acetate depot injections with sham injections before endometrial ablation for the treatment of dysfunctional uterine bleeding (DUB).DesignProspective, randomized, double-blind, parallel-group study.SettingThirty-seven centers in 12 countries.Patient(s)Three-hundred and fifty-eight premenopausal women aged over 30 years with DUB.Intervention(s)Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks, or sham depot every 28 days for 8 weeks, with endometrial ablation 6 weeks +/- 3 days after the first depot injection (i.e., when the endometrium is at its thinnest). The follow-up continued for 3 years.Main outcome measure(s)At the 3-year follow-up, bleeding in the previous 3 months and need for surgical intervention were recorded.Result(s)At 3 years, amenorrhea rates were 21% in the goserelin acetate group and 14% in the control group (estimated odds ratio, 1.8; 95% CI, 0.98-3.25; P=.0571). The surgical intervention rate (since the original procedure) was low and did not differ significantly between groups. For hysterectomy, it was 21% for the goserelin acetate group and 15% for the control group. For repeat ablations, it was 5.6% for the goserelin acetate group and 2.1% for the control group.Conclusion(s)Prethinning with goserelin acetate before endometrial ablation resulted in higher long-term amenorrhea rates than ablation without prethinning.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (6)
- 11 Complications of hysterectomy via openalex
- An economic evaluation of transcervical endometrial resection versus abdominal hysterectomy for the treatment of menorrhagia via openalex
- Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study via openalex
- Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding via openalex
- doi:10.1111/j.1471-0528.1997.tb11003.x via openalex
- doi:10.1016/s1074-3804(98)80047-9 via openalex
Cited by (10)
- Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding 2013
- Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding 2012
- Dysfunctional uterine bleeding: from adolescence to menopause 2010
- Are gonadotropin-releasing hormone analogs and laparoscopic ablation equally effective treatments for endometriosis? 2007
- Intrauterine instillation of trichloroacetic acid is effective for the treatment of dysfunctional uterine bleeding 2005
- A randomised controlled trial of microwave endometrial ablation without endometrial preparation in the outpatient setting: patient acceptability, treatment outcome and costs 2005
- NovaSure impedance controlled system for endometrial ablation: Three-year follow-up on 107 patients 2004
- Current treatment of dysfunctional uterine bleeding 2003
- Chemical ablation of endometrium with trichloroacetic acid 2003
- Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding 2002
Source provenance
- openalex
- last seen: 2026-05-11T06:09:19.794676+00:00
- unpaywall
- last seen: 2026-08-01T06:38:12.426807+00:00
License: CC0
· commercial use OK